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School of Medicine, University of Washington, Seattle, WA, USAA B S T R A C TObjective: The objective of this study was to develop empirical algo-
rithms that estimate health-state utility values from disease-specific
quality-of-life scores in individualswithmigraine.Methods: Data from
cross-sectional, multicountry study were used. Individuals with epi-
odic and chronicmigrainewere randomly assigned to training or valida-
ionsamples. Spearman’s correlationcoefficientsbetweenpairedEuroQol
ve-dimensional (EQ-5D) questionnaire utility values and both Headache
mpact Test (HIT-6) scores and Migraine-Specific Quality-of-Life Ques-
ionnaire version 2.1 (MSQ) domain scores (role restrictive, role preven-
ive, and emotional function) were examined. Regression models were
onstructed to estimate EQ-5Dquestionnaireutility values fromtheHIT-6
core or the MSQ domain scores. Preferred algorithms were confirmed in
he validation samples. Results: In episodic migraine, the preferred
IT-6 and MSQ algorithms explained 22% and 25% of the variance (R2)
in the training samples, respectively, and had similar prediction errors
(root mean square errors of 0.30). In chronic migraine, the preferred
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doi:10.1016/j.jval.2011.12.007HIT-6 and MSQ algorithms explained 36% and 45% of the variance in
the training samples, respectively, and had similar prediction errors
(root mean square errors 0.31 and 0.29). In episodic and chronic mi-
graine, no statistically significant differences were observed between
the mean observed and the mean estimated EQ-5D questionnaire util-
ity values for the preferred HIT-6 andMSQ algorithms in the validation
samples. Conclusions: The relationship between the EQ-5D question-
naire and the HIT-6 or theMSQ is adequate to use regression equations
to estimate EQ-5Dquestionnaire utility values. The preferredHIT-6 and
MSQ algorithms will be useful in estimating health-state utilities in
migraine trials in which no preference-based measure is present.
Keywords: chronicmigraine, episodicmigraine, EQ-5D, HIT-6,mapping,
MSQ, utility.
Copyright © 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
An increasing number of countries have begun using economic
appraisal in reimbursement decisions for pharmaceuticals and
other health interventions [1]. Cost-utility analysis is a form of eco-
omic evaluation frequently used by reimbursement agencies and
ational advisory bodies to make informed decisions on whether or
ot to reimburse new health-care interventions. Health state prefer-
nces (i.e., utilities) are a key component in valuing health outcomes
n this type of analysis in that they are used in calculating quality-
djusted life-years [2]. Unfortunately, many clinical trials include
ealth statusmeasures that lack thepreferenceweightsnecessary to
roduce health-state utility values for use in cost-utility analysis [3].
solution to this problem is to map a nonpreference generic or dis-
ase-specific quality-of-life measure to a generic preference-based
easure, such as the EuroQol five-dimensional (EQ-5D) question-
aire [3,4]. Mapping by statistical association is gaining popularity,
ecause it avoids the arbitrariness of judgment-based mapping
ethods [3,5]. Mapping studies have been performed in many ther-
peutic areas, such as angina [6], stroke [7], Parkinson’s disease [8],
rthritis [9,10], Crohn’s disease [11], obesity [12], cancer [13,14], and
ther diseases. This analysis presents such an exercise for mapping
* Address correspondence to: Patrick J. Gillard, Global Health Outc
Irvine, CA 92612, USA.
E-mail: gillard_patrick@allergan.com.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.rom disease-specific instruments to the EQ-5D questionnaire in in-
ividuals with migraine.
Migraines are characterized as a chronic disorderwith episodic
ttacks that cause substantial functional impairment, disturb so-
ial and family relationships, interfere with workplace productiv-
ty, and negatively impact a patient’s health-related quality of life
HRQOL) [15,16]. Annual direct cost estimates for those with mi-
raine have ranged from $100 to more than $7000 per person per
ear [17]. These unpredictable attacks involve pulsating unilateral
ead pain of moderate-to-severe intensity accompanied by nau-
ea, vomiting, and sensitivity to light and noise [18]. Migraine has
een subdivided into two forms primarily on the basis of headache
ay frequency. Chronic migraine occurs less frequently than does
pisodicmigraine (15 headache days permonth) and is classified
n the International Classification of Headache Disorders, 2nd edition, as
complication of migraine characterized by 15 or more headache
ays per month for at least 3 months, with at least 8 headache
ays per month being migraine or probable migraine [19].
It has been widely reported in clinical and population-based
tudies that chronic migraine characteristically causes greater
eadache-related disability, greater impairment of quality of life,
nd increased resource utilization, compared with episodic mi-
raine [20–23]. Health-care costs over 3 months have been esti-
Strategy and Research, Allergan, Inc., 2525 Dupont Drive, T2-6A,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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486 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 8 5 – 4 9 4mated to be three times higher in individuals with chronic mi-
graine than in those with episodic migraine [24]. Those with
chronicmigraine also have increased rates of medical and psychi-
atric comorbidities and are approximately twice as likely to have
depression, anxiety, and chronic pain conditions [23,25]. The two
most commonly used headache/migraine-specific HRQOL mea-
sures are the Headache Impact Test (HIT-6) [26] and the Migraine-
Specific Quality-of-Life Questionnaire version 2.1 (MSQ) [27]. The
eliability and validity of the HIT-6 and the MSQ have been previ-
usly confirmed in episodic and chronic migraine [28–30].
Although many clinical trials have investigated the use of var-
ous therapies for migraine prophylaxis, few trials have reported
ealth-related utility values because these trials lack a preference-
ased HRQOL instrument [31,32]. A number of researchers believe
hat disease-specific instruments tend to bemore sensitive to clin-
cally important differences [33]. Other investigators do not want
o increase the burden imposed on study subjects by having sub-
ects complete additional questionnaires [13]. Regardless, the lack
f preference-basedmeasures inmigraine prophylaxis trials pres-
nts a considerable barrier in calculating quality-adjusted life-
ears in cost-utilitymodels. This leaves decisionmakerswithout a
ay to adequately compare health-care interventions for mi-
raine prevention.
The primary goal of this analysis was to develop empirical al-
orithms that estimate health-state utility values from the HIT-6
r the MSQ (disease-specific HRQOL scores) in individuals with
igraine. If found sufficiently robust, these mapping algorithms
an then be used to generate health-state utilities from trials that
ave collected data by using the HIT-6 or the MSQ but have not
ollected utility data. This will aid future economic evaluation of
ealth-care interventions for migraine prophylaxis in patients
ith episodic and chronic migraine.
Methods
Source of data
Paired observations from individuals with migraine who partici-
pated in the International Burden of Migraine Study (IBMS) were
included in this analysis. IBMS was a cross-sectional, Web-based
observational survey of participants from the United States, Aus-
tralia, Canada, Germany, United Kingdom, France, Spain, Italy,
Taiwan, and Brazil. Detailed methods and primary results of the
IBMS have been published elsewhere [17,23]. The data used in this
analysis include information from Brazil. This information was
not available for analysis when the initial results of IBMS were
published [23]. Individuals with migraine as defined by the Inter-
national Classification of Headache Disorders, 2nd edition, criteria were
further categorized as having either chronic (15 headache days
per month) or episodic (15 headache days per month) migraine
[18,19].
Instruments
HIT-6
The HIT-6 is a disease-specific HRQOL questionnaire that evalu-
ates six content areas: pain, role functioning, social functioning,
energy/fatigue, cognition, and emotional distress [26–28]. A HIT
score is an indicator of the impact headaches are having on a
person’s daily life and ability to function. Item responses include
“never,” “rarely,” “sometimes,” “very often,” and “always” and are
assigned values of 6, 8, 10, 11, and 13, respectively. Total scores
range from 36 to 78, with higher scores indicating worse HRQOL. A
total score of 49 or less indicates little or no impact, 50 to 55 indi-
cates some impact, 56 to 59 indicates substantial impact, andT C A S R E M E In H * †
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487V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 8 5 – 4 9 4scores greater than 60 reflect severe impact on a person’s daily life
and ability to function.
MSQ
The MSQ version 2.1 is a 14-item HRQOL instrument that mea-
sures three dimensions of functional status specific to migraine
[29,30]. The role preventive (RP) dimension consists of four items
measuring the degree to which the performance of normal activ-
ities is interrupted by migraines. The role restrictive (RR) dimen-
sion consists of seven items measuring the degree to which the
performance of normal activities is limited by migraines. The
emotional function (EF) dimension consists of three items mea-
suring the emotional effects ofmigraine. Items are scored by using
a six-point Likert-type scale: 1 none of the time; 2 a little bit of
he time; 3  some of the time; 4  a good bit of time; 5 most of
he time; and 6  all of the time. Raw dimension scores are
ummed and rescaled on a 0 to 100 scale, where higher scores
ndicate better HRQOL.
EQ-5D questionnaire
The EQ-5D questionnaire is a widely used preference-based ge-
neric HRQOL measure that consists of two components, the self-
classifier and the visual analogue scale. The self-classifier pro-
vides a simple method for capturing self-reported descriptions of
health problems according to a five-dimension classification sys-
tem that includes mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression. Each dimension is composed of
three levels: 1) no problem; 2) some or moderate problems; and 3)
severe or extreme problems. Scores for the five health states can
be converted into a utility value (the EQ-5D questionnaire index
score) by applying preference weights elicited from the US or UK
general populations [34].
Statistical analysis
The strength of overlap between the EQ-5D questionnaire and both
the HIT-6 and the MSQ was evaluated a priori to ensure conceptual
overlap between the EQ-5D questionnaire and the disease-specific
measures. Bivariate analysis between individuals with episodic and
chronic migraine was conducted by using the chi-square test for
categorical variables and the two-sample t test for continuous
ariables. Before analysis, individuals with episodic and chronic
igraine were separated into two distinct groups and then ran-
omized 7:3 into training and validation samples.
All analyses of EQ-5Dquestionnaireutility valueswere in relation
o the corresponding paired HIT-6 scores or MSQ domain scores.
pearman’s correlation coefficients between paired EQ-5D question-
aire utility values (UKvaluation set) and bothHIT-6 scores andMSQ
omain scores were examined. The UK valuation set for raw EQ-5D
uestionnaire scores was chosen because cost-utility analyses are
requently required for the reimbursement of newmedicines by the
cottish Medicine Consortium and the National Institute for Health
nd Clinical Excellence in the United Kingdom. Ordinary least
quared regression models were constructed to estimate EQ-5D
uestionnaire utility values from HIT-6 scores or MSQ domain
cores. Utility values were used as the dependent variable, whereas
he disease-specific scores functioned as the independent variable.
onlinearity in eachmodel was examined by investigating the plots
f residuals, and quadratic terms for HIT-6 and MSQ scores were
dded if nonlinearity was determined to be present. The F test was
sed to assess whether the addition of a covariate (or groups of co-
ariates) significantly improved the fit and predictive accuracy of the
odels. The influence of demographic and clinical variables, such as
ge, sex, race, employment, education, marital status, income, body
ass index, concomitant headache medication, and comorbidities,
as explored. Each of these variables has the potential to impact anindividual’s HRQOL based on the published literature [35–42].
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488 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 8 5 – 4 9 4The size of the prediction error of the models was assessed
by using root mean square error (RMSE). In episodic and chronic
migraine, preferred mapping algorithms for the HIT-6 and the
MSQ were selected on the basis of RMSE in view of variable
coefficient significance, variable impact on RMSE, and model
simplicity. A description of how the covariates in the preferred
algorithms were coded can be found in Appendix I found in
Supplemental Materials at doi:10.1016/j.jval.2011.12.007. The
oefficient of determination (R2) was also used to assess the
goodness of fit of the regression models. R2 is the proportion of
variability in EQ-5D questionnaire utility values that is ac-
counted for by the statistical model. In ordinary least squared
regression, if R2 equals 1, the fittedmodel explains all variability
in EQ-5D questionnaire utility value, whereas an R2 of 0 indi-
ates no “linear” relationship between EQ-5D questionnaire
tility value and the repressors.
For a confirmatory analysis, the preferred models were ap-
lied to the validation samples. Themeans for the observed and
stimated EQ-5D questionnaire utility values were compared by
sing a paired t test. Themean difference between observed and
stimated individual EQ-5D questionnaire utility values for the
referred algorithms was also examined in headache days per
onth groups, defined as 0 to 3, 4 to 9, 10 to 14, 15 to 19, and 20
r more headache days per month. A P value of 0.05 was used to
establish significance. All analyses were undertaken by using
Stata10 (StataCorp LP, College Station, TX) and confirmed in
SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Table 3 – Average HRQOL values of individuals with migra
Instrument Episodic migraine
HIT-6 (total score) 63.4 (n  8501)
MSQ-RR 56.5 (n  8227)
MSQ-RP 71.7 (n  8227)
MSQ-EF 67.2 (n  8227)
EQ-5D questionnaire (UK) 0.68 (n  9160)
EF, emotional function; EQ-5D, EuroQol five-dimensional; HIT-6, Hea
version 2.1; RP, role preventive; RR, role restrictive.
* t Test: Test was performed between individuals with episodic and
Table 4 – Spearman’s correlation coefficients for paired obs
HIT-6 and the MSQ in the training samples.
N (pairs)
Any migraine
HIT-6 6334
MSQ-RR 6108
MSQ-RP 6108
MSQ-EF 6108
Episodic migraine
HIT-6 5961
MSQ-RR 5770
MSQ-RP 5770
MSQ-EF 5770
Chronic migraine
HIT-6 373
MSQ-RR 338
MSQ-RP 338
MSQ-EF 338
EF, emotional function; EQ-5D, EuroQol five-dimensional; HIT-6, Hea
version 2.1; RP, role preventive; RR, role restrictive.Results
Conceptual overlap between HRQOL instruments
The conceptual overlap between the the EQ-5D questionnaire and
both the HIT-6 and the MSQ was established a priori. The domain
coverage of the HIT-6 and the EQ-5D questionnaire overlap on
three dimensions. The “usual activities” dimension in the EQ-5D
questionnaire and “role functioning and social functioning” di-
mensions in the HIT-6 address the impact of illness on the ability
to perform usual activities (e.g., work, study, and social activities);
both the “anxiety/depression” dimension in the EQ-5D question-
naire and the “emotional distress” dimension in the HIT-6 address
feelings of anxiety; and the “pain/discomfort” dimension in the
EQ-5D questionnaire and the “pain” dimension in the HIT-6 cap-
ture the pain associated with illness. Similarly, the content of the
MSQ and the EQ-5D questionnaire overlaps on several dimen-
sions: the “usual activities” dimension in the EQ-5D questionnaire
and “role preventive” and “role restrictive” dimensions in theMSQ
address the impact of illness on the ability to perform usual activ-
ities, and both the “anxiety/depression” dimension in the EQ-5D
questionnaire and the “emotional function” dimension in theMSQ
address feelings of anxiety and depression.
Descriptive summary
The demographic and clinical characteristics of individuals with
migraine by HIT-6 and MSQ completion are presented in Tables 1
Chronic migraine P value*
66.3 (n  547) 0.001
44.4 (n  499) 0.001
61.4 (n  499) 0.001
48.3 (n  499) 0.001
0.46 (n  555) 0.001
e Impact Test; MSQ, Migraine-Specific Quality-of-Life Questionnaire
ic migraine.
tions between the EQ-5D questionnaire (UK) and the
EQ-5D questionnaire P value
0.0001
0.25
0.31
0.32
0.33
0.0001
0.23
0.29
0.30
0.31
0.0001
0.42
0.50
0.55
0.39
e Impact Test; MSQ, Migraine-Specific Quality-of-Life Questionnaireine.
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489V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 8 5 – 4 9 4and 2. The number of subjects who completed the HIT-6 and the
MSQ differ because the MSQ was not administered in Brazil while
the HIT-6 was not administered in Taiwan. Individuals with
chronic migraine differed from those with episodic migraine in
age, race, employment, body mass index, headache medication
use, and proportion with comorbidities (P  0.04). The average
HRQOL values of the HIT-6, theMSQ, and the EQ-5D questionnaire
in individuals with migraine are provided in Table 3. Individuals
with chronic migraine had significantly worse HRQOL scores than
did individuals with episodic migraine (P  0.0001).
Spearman’s correlation
Correlation coefficients for paired observations between the
EQ-5D questionnaire utility values and both HIT-6 scores andMSQ
dimension scores were statistically significant in individuals with
anymigraine, episodicmigraine, and chronicmigraine (P 0.0001)
(Table 4). The strongest correlation for individuals with migraine
was between the MSQ-EF and the EQ-5D questionnaire (0.33), and
the weakest correlation was between the HIT-6 and the EQ-5D
questionnaire (0.25). The correlations between the EQ-5D ques-
tionnaire utility values and both HIT-6 scores andMSQ dimension
scores were stronger in individuals with chronic migraine than in
those with episodic migraine (Table 4).
Models
Several regression models were explored in view of variable
impact on RMSE, variable coefficient significance, and model
simplicity. The RMSE and R2 statistics for the chosen preferred
IT-6 and MSQ regression models in migraine are presented in
ables 5 and 6, respectively. The preferred models were the
ame in episodic and chronicmigraine. Both the preferred HIT-6
nd MSQ algorithms included covariates for age, sex, race, em-
loyment status, headache medication use, and comorbidities.
ody mass index, marital status, and income were not included
n the preferred models. The coefficients for these three vari-
Table 5 – Models for paired HIT-6/EQ-5D questionnaire obs
Migraine type
Mo
N (pairs) 5961
A 1.
1 HIT-6 0.
2 Age
3 Male
4 White
5 Employment (full or part time)
6 Headache medication (acute and/or prophylaxis)
‡
7 Pain condition
8 Vascular condition
9 Psychiatric condition
10 Other condition
R2 0.
Adjusted R2 0.
RMSE 0.
MSE 0.
Model 1: EQ-5D questionnaire    1 HIT6  error.
Model 2*: EQ-5D questionnaire    1 HIT6  2 age  3 male  4
 8 vascular condition  9 psychiatric condition  10 other con
EQ-5D, EuroQol five-dimensional; HIT-6, Headache Impact Test; MSE
* Preferred HIT-6 mapping algorithm.
† P  0.05.
‡ Over the last 3 mo.bles were statistically insignificant in all models, and their
mpact on the predictive accuracy of themodels were negligible.
HIT-6/EQ-5Dquestionnaire residual plots suggested a degree of
onlinearity in the relationship between these measures. As a re-
ult, the addition of a HIT-6 quadratic term was explored to im-
rove the goodness of fit of the HIT-6 models. Little improvement
n performance was gained in the HIT-6 models by adding this
ariable, and so it was decided to not keep the quadratic term in
he preferred HIT-6 algorithm. The MSQ/EQ-5D questionnaire re-
idual plots did not suggest nonlinearity; therefore, a quadratic
erm was not considered for the preferred MSQ algorithm. The
referred HIT-6 algorithm was a linear model, which explained
2% of the variance in the episodic migraine training sample and
6% in the chronic migraine training sample. The RMSE of the
referred the HIT-6 model was 0.30 in episodic migraine and 0.31
n chronic migraine. The preferred model was as follows:
EQ-5D questionnaire    1 HIT-6  2 age  3 male  4
white 5 employment 6 headache medication 7 pain con-
dition  8 vascular condition  9 psychiatric condition  10
other condition (Table 5).
The preferred MSQ algorithm was also a linear model with
covariates representing each MSQ domain that explained 25% of
the variance in the episodic migraine training sample and 45% in
the chronic migraine training sample. The RMSE of the preferred
MSQ model was 0.30 in episodic migraine and 0.29 in chronic mi-
graine. The preferred model was as follows:
EQ-5D questionnaire    1 MSQ-RP  2 MSQ-RR  3
MSQ-EF  4 age  5 male  6 white  7 employment  8
headache medication  9 pain condition  10 vascular
condition  11 psychiatric condition  12 other condition
(Table 6).
Confirmatory analysis
The results of the confirmatory analyses are presented in Table 7
(HIT-6) and Table 8 (MSQ). In episodic migraine, there was no sta-
tions for individuals with migraine.
isodic migraine Chronic migraine
1 Model 2* Model 1 Model 2*
4296 373 292
1.4615† 2.5525† 2.2465†
† 0.0112† 0.0313† 0.0231†
0.0003 0.0007
0.0022 0.0466
0.0075 0.0451
0.0864† 0.1166†
0.0395† 0.1001
0.1537† 0.1325†
0.0050 0.0461
0.1548† 0.1999†
0.04150† 0.0273
0.22 0.19 0.36
0.22 0.19 0.34
0.30 0.33 0.31
0.090 0.112 0.095
e  5 employment  6 headache medication  7 pain condition
.
n squared error; RMSE, root mean squared error.erva
Ep
del
6055†
01483
08
08
32
105
whit
dition
, mea
490 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 8 5 – 4 9 4tistically significant difference between themean observed EQ-5D
questionnaire utility value (0.676) and the mean estimated EQ-5D
questionnaire utility value (0.673) by using the preferred HIT-6
algorithm. Neither was there a statistically significant difference
between the mean observed EQ-5D questionnaire utility value
(0.433) and the mean estimated EQ-5D questionnaire utility value
(0.493) in the chronic migraine validation sample (Table 7).
Similarly, there was no statistically significant difference be-
tween the mean observed EQ-5D questionnaire utility value (0.689)
and themean estimated EQ-5D questionnaire utility value (0.670) by
Table 6 – Models for paired MSQ/EQ-5D questionnaire obse
Migraine type
Mo
N (pairs) 5770
A 0
1 MSQ-RP 0
2 MSQ-RR 0
3 MSQ-EF 0
4 Age
5 Male
6 White
7 Employment (full or part time)
8 Headache medication (acute and/or prophylaxis)
‡
9 Pain condition
10 Vascular condition
11 Psychiatric condition
12 Other condition
R2 0
Adjusted R2 0
RMSE 0
MSE 0
Model 1: EQ-5D questionnaire    1 MSQ-RP  2 MSQ-RR  3 MS
Model 2*: EQ-5D questionnaire    1 MSQ-RP  2 MSQ-RR  3 M
medication  9 pain condition  10 vascular condition  11 psy
EF, emotional function; EQ-5D, EuroQol five-dimensional; MSE, me
Version 2.1; RMSE, root mean squared error; RP, role preventive; RR,
* Preferred MSQ algorithms.
† P  0.05.
‡ Over the last 3 mo.
Table 7 – Comparison of observed EQ-5D questionnaire an
validation samples (preferred HIT-6 algorithms).
Episodic migraine
EQ-5D questionnaire observed values
EQ-5D questionnaire estimated values
Mean difference (95% CI) 0.00
P value*
RMSE
MSE
Chronic migraine
EQ-5D questionnaire observed values
EQ-5D questionnaire estimated values
Mean difference (95% CI) 0.05
P value*
RMSE
MSE
CI, confidence interval; EQ-5D, EuroQol five-dimensional; MSE, mean
* P value for paired t test for comparison between observed and estimatedusing the preferred MSQ algorithm in the episodic migraine valida-
tion sample. Neither was there a statistically significant difference
between themeanobservedEQ-5Dquestionnaireutility value (0.449)
and the mean estimated EQ-5D questionnaire utility value (0.450) in
the chronic migraine validation sample (Table 8).
For the preferred HIT-6 and MSQ algorithms, the mean differ-
ence between observed and estimated EQ-5D questionnaire utility
values was also determined not to be statistically different in the
headache days per month groups (P  0.05; Table 9 [HIT-6] and
Table 10 [MSQ]).
ions for individuals with migraine.
isodic migraine Chronic migraine
1 Model 2* Model 1 Model 2*
4144 338 260
† 0.4509† 0.0492 0.1409
† 0.0023† 0.0065† 0.0056†
0.0001 0.0013 0.0011
† 0.0019† 0.0011 0.0002
0.0001 0.0021
0.0073 0.0043
0.0163 0.0514
0.0689† 0.1317†
0.0287 0.0300
0.1490† 0.1155†
0.0160 0.0237
0.1443† 0.1695†
0.0210 0.0159
0.25 0.30 0.45
0.25 0.30 0.42
0.30 0.32 0.29
0.090 0.104 0.087
 error.
 4 age  5 male  6 white  7 employment  8 headache
ric condition  12 other condition.
uared error; MSQ, Migraine-Specific Quality-of-Life Questionnaire
estrictive.
imated EQ-5D questionnaire utility values in the
ean SD N
.676 0.328 2540
.673 0.156 1836
.015 to 0.012) 0.295 1836
.79
.29
.086
.433 0.383 174
.493 0.225 139
.104 to 0.002) 0.314 139
.06
.31
.098
red error; RMSE, root mean squared error.rvat
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Although the use of a preference-based HRQOL measure is the
ideal method to generate health-state utility values in migraine
prophylaxis trials, the preferred HIT-6 and MSQ mapping algo-
rithms appear adequate to estimate EQ-5D questionnaire utility
values in individuals with episodic and chronic migraine. HIT-6
and MSQ mapping algorithms will be useful in estimating health-
state utilities in trials of patients with migraine that contain the
HIT-6 or the MSQ but lack a preference-based HRQOL measure.
The relationship between the EQ-5D questionnaire and the
HIT-6 and the MSQ was explored for two reasons. A migraine pro-
phylaxis clinical trial may contain only one of the disease-specific
instruments, and the conceptual overlap between the EQ-5Dques-
tionnaire and both the HIT-6 and the MSQ appeared sufficiently
strong to map from both disease-specific instruments in episodic
and chronicmigraine. The results of this study indeed suggest that
HIT-6/EQ-5D questionnaire and the MSQ/EQ-5D questionnaire re-
lationships are adequate for mapping. The preferred HIT-6 and
MSQ algorithms had approximately the same prediction errors in
episodic (RMSEs 0.30) and chronic migraine (0.31 vs. 0.29). The
preferred HIT-6 and MSQ algorithms also explained a similar pro-
portion of variance in the EQ-5D questionnaire in episodic (R2 of
.22 vs. 0.25) and chronic migraine (0.36 vs. 0.45). Both preferred
lgorithms were confirmed in the episodic and chronic migraine
alidation samples.
The preferred algorithms include covariates for age, sex, race,
mployment, headache medication use, and comorbidities. This
equires that any trial in which the preferred algorithms are to be
sed also include these variables. Because this may be problem-
tic and limit the use of these algorithms, simpler models were
xplored in the training samples (Tables 5 and 6). In episodic mi-
raine, the RMSE was slightly higher for the simple HIT-6 model
han for the preferred HIT-6 algorithm. In chronic migraine, the
MSE was slightly higher for the simple HIT-6 model. Similarly,
ith the MSQ algorithm, the RMSE was slightly higher in the sim-
lemodel comparedwith the preferredMSQ algorithm in episodic
igraine. In chronic migraine, the RMSE was slightly higher for
he simple MSQ model. Although the simple HIT-6 and MSQ algo-
ithms appear to be inferior to the preferred models, as judged by
heir predictive accuracy (RMSE), both simpler models (HIT-6 and
SQ) were confirmed in the episodic and chronicmigraine valida-
ion samples (confirmation results available upon request). These
Table 8 – Comparison of observed EQ-5D questionnaire an
validation samples (preferred MSQ algorithms).
Episodic migraine
EQ-5D questionnaire observed values
EQ-5D questionnaire estimated values
Mean difference (95% CI) 0.013
P value*
RMSE
MSE
Chronic migraine
EQ-5D questionnaire observed values
EQ-5D questionnaire estimated values
Mean difference (95% CI) 0.01
P value*
RMSE
MSE
CI, confidence interval; EQ-5D, EuroQol five-dimensional; MSE, mean
* P value for paired t test for comparison between observed and estimesults suggest that the simpler mapping algorithms may be usedo estimate EQ-5D questionnaire utility values when data avail-
bility inhibits the use of the preferred models.
Although there is no standard on which mapping algorithms
re judged, the preferred mapping algorithms had prediction er-
ors that are only slightly higher than other publishedmodels and
ave explanatory powers that fall within the range of other pub-
ished studies. In published mapping algorithms, R2 has ranged
from less than 0.2 to greater than 0.6 and RMSE has ranged from
0.084 to 0.2 [3]. In this study, the R2 of the preferredHIT-6 algorithm
n episodic and chronic migraine was 0.22 and 0.36 and the RMSE
as 0.30 and 0.31, respectively. The R2 of the preferred MSQ algo-
rithm in episodic and chronic migraine was 0.25 and 0.45 and the
RMSE was 0.30 and 0.29, respectively. In published mapping algo-
rithms, RMSEs also typically represent percentage error of up to
15%of the overall range of the dependent variable [3]. In this study,
EQ-5D questionnaire scores ranged from 0.594 to 1, and so the
RMSE of the preferred algorithms represented percentage error of
approximately 18% in both migraine populations. This observed
percentage error is only slightly higher than that of other pub-
lished mapping algorithms.
A few mapping studies have reported that the degree of pre-
dictive error is not evenly distributed across the scale of the de-
pendent variable, with less accurate predictions for poor health
states [3,43–45]. In light of these findings, the decision to develop
mapping algorithms in episodic and chronic migraine is further
substantiated. The HRQOL differences between these two popula-
tions (Table 3) suggest that individualswith chronicmigraine have
poorer health than do those individuals with episodicmigraine. In
developing separatemappingmodels for chronic and episodicmi-
graine, the potential for overprediction of utility values for indi-
viduals in poor health (i.e., individuals with chronic migraine) is
reduced. Nevertheless, the tendency for mapping algorithms to
overestimate utility values is still important to consider when us-
ing the preferred HIT-6 and MSQ algorithms to estimate EQ-5D
questionnaire utility values for cost-utility analysis. It is likely that
the preferred algorithms will still overestimate EQ-5D question-
naire utility values for individualswithmore severe diseasewithin
each migraine population.
There are several limitations of this study. First, a concern in
many mapping algorithms is whether the generic measure is ap-
propriate for the disease under investigation. If a generic instru-
ment is insensitive to changes in a particular disease state, amap-
ping function that maps from a disease-specific measure to this
imated EQ-5D questionnaire utility values in the
ean SD N
689 0.324 2457
670 0.170 1728
.000 to 0.027) 0.291 1728
06
29
084
449 0.370 161
450 0.259 126
069 to 0.049) 0.333 126
74
31
096
red error; RMSE, root mean squared error.
values.d est
M
0.
0.
3 (0
0.
0.
0.
0.
0.
(0.
0.
0.
0.
squageneric measure will perform poorly [3]. This was determined not
Table 9 – Comparison of observed EQ-5D questionnaire and estimated EQ-5D questionnaire utility values in headache days per month groups in the validation
samples (preferred HIT-6 algorithms).
Headache days per month
Episodic migraine Chronic migraine
0–3 4–9 10–14 15–19 20–23 24
n (observed) 1690 679 171 47 79 48
Mean observed EQ-5D questionnaire score
(SD)
0.700 (0.320) 0.633 (0.343) 0.608 (0.332) 0.51 (0.360) 0.468 (0.370) 0.300 (0.398)
n (estimated) 1193 511 132 40 60 39
Mean estimated EQ-5D questionnaire
score (SD)
0.687 (0.154) 0.647 (0.158) 0.645 (0.148) 0.571 (0.204) 0.482 (0.222) 0.429 (0.232)
Mean difference (95% CI) 0.007 (0.01 to 0.023) 0.008 (0.034 to 0.018) 0.054 (0.107 to
0.001)
0.072 (0.187 to 0.042) 0.015 (0.097 to 0.066) 0.084 (0.168 to 0.000)
P value* 0.42 0.52 0.05 0.210 0.71 0.05
CI, confidence interval; EQ-5D, EuroQol five-dimensional; HIT-6, Headache Impact Test.
* P value for paired t test for comparison between observed and estimated values.
Table 10 – Comparison of observed EQ-5D questionnaire and estimated EQ-5D questionnaire utility values in headache days per month groups in the validation
samples (preferred MSQ algorithms).
Headache days per month
Episodic migraine Chronic migraine
0–3 4–9 10–14 15–19 20–23 24
n (observed) 1693 616 148 55 49 57
Mean observed EQ-5D questionnaire score (SD) 0.716 (0.306) 0.647 (0.344) 0.555 (0.377) 0.606 (0.290) 0.450 (0.390) 0.296 (0.364)
n (estimated) 1145 472 111 42 40 44
Mean estimated EQ-5D questionnaire score
(SD)
0.691 (0.164) 0.637 (0.174) 0.596 (0.176) 0.531 (0.233) 0.423 (0.257) 0.397 (0.270)
Mean difference (95% CI) 0.014 (0.003 to 0.03) 0.027 (0.00 to 0.054) 0.047 (0.113 to 0.018) 0.063 (0.03 to 0.156) 0.006 (0.111 to 0.122) 0.094 (0.192 to 0.004)
P value* 0.103 0.05 0.154 0.180 0.925 0.06
CI, confidence interval; EQ-5D, EuroQol five-dimensional.
* P value for paired t test for comparison between observed and estimated values.
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493V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 8 5 – 4 9 4to be the case in this study. Second, the mapping algorithms were
validated through a split-sample confirmatory analysis. Although
thismethod of assessingmodel performance is superior towithin-
sample testing, confirming the algorithms in an independent data
set would be best and is a potential area of future work. Third, the
cross-sectional design of IBMS, the study in which the data were
originally gathered, allows data collection to take place only at a
single time point. Therefore, changes over time cannot be as-
sessed. This limitation is particularly relevant in individuals with
migraine where the time since last migraine or other intermittent
factors can influence how an individual reports his or her HRQOL.
Only a longitudinal study would allow for the assessment of
HRQOL over time.
The multinational character of IBMS may also be viewed as a
limitation by regional health technology bodies due to these as-
sessment centers being mainly concerned with a migraine popu-
lation within a defined area. For example, the Scottish Medicine
Consortium prefers data to be specific to the United Kingdom
when submitting a new medicine for reimbursement. The data
used in IBMS were also collected electronically. This collection
method may introduce a participation bias, because individuals
lacking appropriate computer skills and/or access would not have
been contacted. The clinical information collected was also based
on respondent self-report. Ideally, self-reported information is
validated through medical records or diagnostic information.
These steps were not carried out in IBMS. Lastly, complete clinical
information was not ascertained. Consequently, potential map-
ping algorithms were limited to those variables collected.
The use of mapping algorithms to generate health-state utility
values where there is no preference-based measure has become
exceedingly important for the economic appraisal of health-care
interventions. The preferredmapping algorithms identified in this
analysis will be of value for cost-utility analyses for migraine pro-
phylaxis.Migraine prophylaxis treatments that do not have a pref-
erence-based HRQOL measure in clinical trials can now be com-
pared with one another through cost-utility assessment.
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